About Sodium- and chloride-dependent glycine transporter 2
Sodium- and chloride-dependent glycine transporter 2 (SLC6A5) is a protein
from Homo sapiens identified by UniProt accession
Q9Y345, 797 residues long.
MolForge cross-references it against 1 known binders and
84 disease associations.
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
Disease associations (84)
Diseases linked to this target (Open Targets).
- hereditary hyperekplexia · score 0.74
- hyperekplexia · score 0.48
- Exaggerated startle response · score 0.42
- genetic disorder · score 0.41
- brain disease · score 0.37
- DNA methylation · score 0.21
- cutaneous melanoma · score 0.18
- carotid artery intima media thickness · score 0.10
- autosomal recessive spondylocostal dysostosis · score 0.06
- adolescent idiopathic scoliosis · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Experimental structures are not indexed in MolForge yet —
search RCSB PDB for Q9Y345.
Amino-acid sequence (797 residues)
MDCSAPKEMN KLPANSPEAA AAQGHPDGPC APRTSPEQEL PAAAAPPPPR VPRSASTGAQ TFQSADARAC EAERPGVGSC KLSSPRAQAA SAALRDLREA QGAQASPPPG SSGPGNALHC KIPFLRGPEG DANVSVGKGT LERNNTPVVG WVNMSQSTVV LATDGITSVL PGSVATVATQ EDEQGDENKA RGNWSSKLDF ILSMVGYAVG LGNVWRFPYL AFQNGGGAFL IPYLMMLALA GLPIFFLEVS LGQFASQGPV SVWKAIPALQ GCGIAMLIIS VLIAIYYNVI ICYTLFYLFA SFVSVLPWGS CNNPWNTPEC KDKTKLLLDS CVISDHPKIQ IKNSTFCMTA YPNVTMVNFT SQANKTFVSG SEEYFKYFVL KISAGIEYPG EIRWPLALCL FLAWVIVYAS LAKGIKTSGK VVYFTATFPY VVLVILLIRG VTLPGAGAGI WYFITPKWEK LTDATVWKDA ATQIFFSLSA AWGGLITLSS YNKFHNNCYR DTLIVTCTNS ATSIFAGFVI FSVIGFMANE RKVNIENVAD QGPGIAFVVY PEALTRLPLS PFWAIIFFLM LLTLGLDTMF ATIETIVTSI SDEFPKYLRT HKPVFTLGCC ICFFIMGFPM ITQGGIYMFQ LVDTYAASYA LVIIAIFELV GISYVYGLQR FCEDIEMMIG FQPNIFWKVC WAFVTPTILT FILCFSFYQW EPMTYGSYRY PNWSMVLGWL MLACSVIWIP IMFVIKMHLA PGRFIERLKL VCSPQPDWGP FLAQHRGERY KNMIDPLGTS SLGLKLPVKD LELGTQC
Explore Sodium- and chloride-dependent glycine transporter 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets